This Viewpoint discusses the potential impact on recruitment, retention, measurement, or evidence generation after a prediction market platform announced it would host betting on the outcomes of clinical trials and US Food and Drug Administration regulatory reviews, noting that policy action is needed to ensure that prediction markets do not undermine the public interest.
No takes yet. Share an insight, caveat, or question.
Lusk et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: